GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Biocon Ltd

Biocon Q2 FY27 Standalone Profit Rises to Rs. 917 Million; CTO Change Noted

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 04 Nov 2026, 01:21 PM IST  ·  BSE ID: 1734783b-2159-472f-b372-6b2e0d66c7a3
View Original BSE Filing (PDF)
💡
In Simple Terms
Biocon reported higher quarterly profits and appointed a new Chief Technology Officer with extensive experience in digital transformation.
🤖 AI Summary
  • Biocon reported standalone Profit for Q2 FY27 at Rs. 917 Million, up from Rs. 709 Million in Q2 FY26.
  • Revenue from operations for Q2 FY27 stood at Rs. 6,305 Million, compared to Rs. 5,833 Million in Q2 FY26.
  • Dr. Mandar Shrikant Ghatnekar resigned as Chief Technology Officer, effective December 31, 2026.
  • Mr. Mukesh Rathi appointed as Chief Technology Officer, effective January 01, 2027, bringing 27 years of experience.
  • Total comprehensive income for Q2 FY27 was Rs. 856 Million, compared to Rs. 718 Million in Q2 FY26.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Profit for the period/ year (Q2 FY27)
917 Million
29.34%
Revenue from operations (Q2 FY27)
6,305 Million
8.09%
Total income (Q2 FY27)
7,212 Million
0.57%
Other income (Q2 FY27)
907 Million
-32.12%
Basic Earnings per share (Q2 FY27)
0.56
1.82%
🏢 How This Affects the Company
📈
Business Impact
The appointment of Mr. Mukesh Rathi as Chief Technology Officer, with experience in digital transformation and AI strategy, indicates a focus on leveraging technology for business performance and innovation. This leadership change could influence future strategic initiatives in technology and digital capabilities.
💰
Financial Impact
Biocon's standalone Profit for Q2 FY27 increased to Rs. 917 Million, reflecting a 29.34% year-over-year growth. This improved profitability was supported by a 8.09% increase in revenue from operations to Rs. 6,305 Million compared to the prior year's quarter.
⚙️
Operational Impact
The transition in the Chief Technology Officer role means a new leader will oversee technological strategy and operations from January 01, 2027. This change could lead to new approaches in process excellence, digital initiatives, and technology management.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this filing.
👤
Who Is Affected
Shareholders are affected by the company's financial performance, with basic earnings per share at Rs. 0.56 for Q2 FY27, up from Rs. 0.55 in Q2 FY26. Management changes impact all shareholders through strategic direction.
🔍
Management Signal
The Board's approval of financial results and the appointment of a new Chief Technology Officer signals ongoing operational management and a strategic focus on strengthening technological leadership.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — assess sustained profit and revenue growth.
Any further announcements regarding new CTO's strategic technology initiatives.
Review consolidated financial results for full group performance.
LOW RISK The filing reports positive financial results and a planned management transition, with no immediate red flags.
💡 Investor Takeaway
Biocon reported a standalone Profit of Rs. 917 Million for Q2 FY27, a 29.34% increase from Rs. 709 Million in Q2 FY26. Revenue from operations for the quarter grew 8.09% to Rs. 6,305 Million. The company also announced the appointment of Mr. Mukesh Rathi as the new Chief Technology Officer, effective January 01, 2027.
⚖️ Strengths & Concerns

✅ Positives

  • Standalone Profit for Q2 FY27 increased by 29.34% to Rs. 917 Million, compared to Rs. 709 Million in Q2 FY26.
  • Revenue from operations grew by 8.09% to Rs. 6,305 Million in Q2 FY27, up from Rs. 5,833 Million in Q2 FY26.

⚠️ Concerns

  • Other income for Q2 FY27 decreased by 32.12% to Rs. 907 Million, compared to Rs. 1,338 Million in Q2 FY26.
  • Current tax charge in Q2 FY27 increased significantly to Rs. 253 Million from Rs. 32 Million in Q2 FY26.
📅 Company Track Record
Biocon reported a standalone profit of Rs. 709 Million in Q2 FY26, as per previous filings, which showed a profit of Rs. 626 Million for the half-year ended September 30, 2025. For the full year ended March 31, 2026, the company reported a standalone profit of Rs. 372 Million.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Biocon's standalone net profit for Q2 FY27?
Biocon's standalone net profit for the quarter ended September 30, 2026 (Q2 FY27) was Rs. 917 Million, representing a 29.34% increase from Rs. 709 Million in Q2 FY26.
What was Biocon's revenue from operations in Q2 FY27?
Biocon's revenue from operations for Q2 FY27 was Rs. 6,305 Million, an 8.09% increase compared to Rs. 5,833 Million in Q2 FY26.
Who is the new Chief Technology Officer appointed at Biocon?
Mr. Mukesh Rathi has been appointed as the Chief Technology Officer (Senior Management Personnel) of Biocon Limited, effective from January 01, 2027.
When did Dr. Mandar Shrikant Ghatnekar's resignation as CTO become effective?
Dr. Mandar Shrikant Ghatnekar's resignation as the Chief Technology Officer of Biocon Limited became effective from the close of business hours of December 31, 2026.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.